INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) InvestorsBusiness Wire • 01/21/22
DEADLINE: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWNewsfile Corp • 01/21/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of InvestorsBusiness Wire • 01/20/22
Shareholder Alert: Robbins LLP Informs Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading ShareholdersBusiness Wire • 01/20/22
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 01/20/22
The Law Offices of Frank R. Cruz Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of InvestorsBusiness Wire • 01/20/22
ALERT: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWBusiness Wire • 01/20/22
NRX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 01/20/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of InvestorsBusiness Wire • 01/19/22
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. (NRXP; NRXPW)Newsfile Corp • 01/19/22
NRXP EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – NRXP; NRXPWBusiness Wire • 01/19/22
NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved TreatmentsBenzinga • 01/18/22
NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved TreatmentsGlobeNewsWire • 01/18/22
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate RightsBenzinga • 01/13/22
NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief TherapeuticsPRNewsWire • 01/12/22
NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron VariantGlobeNewsWire • 01/11/22
NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 VaccineGlobeNewsWire • 01/07/22
NRx Pharmaceutical's Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual ConferenceGlobeNewsWire • 01/07/22
NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved TherapiesPRNewsWire • 01/05/22
NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human UsePRNewsWire • 01/03/22